PC
BPMC

PointState Capital’s Blueprint Medicines BPMC Stock Holding History

PointState Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-129,500
Closed -$5.18M – 141
2017
Q1 		$5.18M Buy
+129,500
New +$4.64M 0.05% 111

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PointState Capital's BPMC Position: Q2 2017 in Review

PointState Capital sold out of Blueprint Medicines (BPMC) in Q2 2017, closing a stake of 129,500 shares — an estimated $5.18M sold.

PointState Capital first reported a position in BPMC in Q1 2017 and held it in 1 quarter. The position peaked at $5.18M in Q1 2017. 124 funds tracked by Wall St. Rank hold BPMC as of Q2 2017.

  • PointState Capital reported no remaining Blueprint Medicines position as of Q2 2017 after selling out during the quarter.
  • PointState Capital sold 129,500 Blueprint Medicines shares in Q2 2017, an estimated $5.18M.
  • PointState Capital first reported a position in Blueprint Medicines in Q1 2017 and held it in 1 quarter.
  • PointState Capital's Blueprint Medicines position peaked at $5.18M in Q1 2017.
  • 124 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2017.

Based on PointState Capital's 13F filing for Q2 2017, filed 14 Aug 2017.